![]() |
|
|
Vol. 289, Issue 3, 1575-1583, June 1999
1 Adrenoceptors in Rat Tissues in Relation to the
Pharmacokinetics
Department of Biopharmacy, School of Pharmaceutical Sciences,
University of Shizuoka, Shizuoka, Japan
The present study was undertaken to simultaneously measure
1 adrenoceptors in rat tissues by
[3H]tamsulosin in vivo. In vivo specific
[3H]tamsulosin binding was observed in the prostate, vas
deferens, aorta, submaxillary gland, spleen, heart, lung, and kidney
after i.v. injection of the ligand but not in the cerebral cortex and liver. Specific [3H]tamsulosin binding in the kidney,
lung, heart, and spleen was greatest at 3 min after i.v. injection and
declined rapidly with the disappearance of [3H]tamsulosin
from the plasma. On the other hand, [3H]tamsulosin
binding in the prostate and aorta peaked at 10 to 60 min after i.v.
injection, and a considerable level of specific binding in both tissues
persisted up to 240 min. The most sustained binding of
[3H]tamsulosin occurred in the submaxillary gland. In
vivo specific [3H]tamsulosin binding in rat tissues was
effectively inhibited by the coinjection of low doses of unlabeled
tamsulosin, prazosin, and terazosin with the radioligand but not by
relatively high doses of yohimbine and propranolol. Based on estimated
ID50 values, in vivo inhibitory effect of tamsulosin
compared with prazosin was 5 to 14 times greater in rat tissues except
the spleen, which showed 1.6 times less potent than prazosin. From
ratios of ID50 (spleen) to ID50 (submaxillary
gland) or ID50 (prostate), tamsulosin was 9 and 19 times,
respectively, greater than prazosin in selectivity of
1
adrenoceptors in the submaxillary gland and prostate versus the spleen,
respectively, suggesting that tamsulosin binds to
1A
subtype with higher affinity than
1B subtype in vivo.
The present study suggests that [3H]tamsulosin is a
useful radioligand for in vivo measurement of
1
adrenoceptors in rat tissues.
This article has been cited by other articles:
![]() |
T. Oki, A. Toma-Okura, and S. Yamada Advantages for Transdermal over Oral Oxybutynin to Treat Overactive Bladder: Muscarinic Receptor Binding, Plasma Drug Concentration, and Salivary Secretion J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1137 - 1145. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yamada, T. Okura, R. Kimura, Y. Deguchi, Y. Suzuki, T. Kobayashi, and K. Aisaka Disposition and alpha 1-Adrenoceptor Binding Characteristics of JTH-601 and Its Metabolites in Rat Tissues Drug Metab. Dispos., April 13, 2001; 28(12): 1487 - 1492. [Abstract] [Full Text] |
||||
![]() |
S. Yamada, T. Okura, and R. Kimura In Vivo Demonstration of {alpha}1A-Adrenoceptor Subtype Selectivity of KMD-3213 in Rat Tissues J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 160 - 167. [Abstract] [Full Text] |
||||